Goodwin Procter attorneys recently advised Gallus BioPharmaceuticals in its sale to DPx Holdings, parent company of Patheon, DSM Fine Chemicals and Banner Life Sciences. Goodwin also advised financial sponsor Ridgemont Equity Partners of Charlotte, N.C. and the senior management team of Gallus in the transaction. The transaction closed on September 29, 2014.
Goodwin previously advised Gallus on its founding and investment from Ridgemont Equity Partners in 2011, which was the result of a year-long effort by Goodwin attorneys John LeClaire and Kingsley Taft to help founder Mark Bamforth launch the company. LeClaire and Taft also introduced the company to financial partners resulting in the Ridgemont investment. Read more about the history of the investment.
Gallus BioPharmaceuticals, based in St. Louis, Mo., is a full service biopharmaceutical contract development and manufacturing organization. The company has facilities in St. Louis and Princeton, N.J., both with exemplary quality and regulatory records, and now supports seven of the top 15 pharmaceutical companies, as well as a growing number of emerging and mid-sized biotechs, in bringing new molecules to the clinic. Gallus was established in 2010 and has 370 employees.
Ridgemont Equity Partners is a private equity firm that provides buyout and growth capital to closely-held private companies and new business platforms. The firm focuses on investments of $25 million to $100 million in industries including basic industries and services, energy, healthcare, and telecommunications/ media/ technology. Since 1993, Ridgemont principals have invested over $3 billion.
DPx Holdings B.V., headquartered in Durham, N.C., is the privately held parent company of the Patheon, DSM Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of a deal between JLL Partners and Royal DSM and has more than 8,000 employees at 20 locations across North America, Europe, Latin America and Australia.
The Goodwin team advising on the transaction was led by partners John LeClaire, Josh Klatzkin and Mark Kirshenbaum, and senior associate Chris Dwyer. Additional support was provided by counsel Todd Hahn and Kirby Lewis, and associates Naina Bhadra, Julia Boyd and Argyrios Saccopoulos.